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We are grateful to Dr Kounis and Dr Soufras 
for their thoughtful insight into the mechanisms 
of anaphylactic shock and their evaluation of our 
article entitled “Major contribution of vasospasm-
-induced coronary blood flow reduction to anaphy-
lactic ventricular dysfunction assessed in isolated 
blood-perfused rat heart” [1].
As Dr Kounis and Dr Soufras pointed out, the 
current consensus on the mechanisms of anaphyla-
ctic shock may be that anaphylactic hypotension is 
caused primarily by reduction in effective circulating 
blood volume which results from systemic vasodila-
tation with the peripheral pooling and increased 
vascular permeability with a shift of intravascular 
fluid to the extravascular space [2]. We have further 
suggested that anaphylactic hypotension involves 
hepatic venoconstriction, as well as blood pooling, 
and extravasation in splanchnic organs [3, 4]. Re-
duced venous return and resultant depression of 
cardiac output would cause coronary hypoperfusion, 
myocardial damage, and ventricular dysfunction.
Nevertheless, we agree with Dr Kounis and 
Dr Soufras in that myocardial ischemia induced by 
coronary spasm is involved in the pathogenesis of 
anaphylactic shock. In our most recent study [1], 
we specifically addressed the question of whether 
the cardiac failure during anaphylaxis is primarily 
due to coronary vasoconstriction-induced myocar-
dial ischemia or the direct negative inotropic effect 
of chemical mediators, using the method of the 
imposed constriction of coronary artery to reprodu-
ce the reduction in coronary blood flow during rat 
cardiac anaphylaxis. Consistent with the concept 
of ’Kounis syndrome’, our study suggests that 
anaphylactic ventricular dysfunction is attributed 
mainly to vasoconstriction-induced coronary flow 
reduction and resultant myocardial ischemia. As 
pointed out by Dr Kounis and Dr Soufras, other 
experimental and clinical studies also suggest the 
involvement of myocardial ischemia via corona-
ry vasoconstriction and ventricular contractile 
failure in the pathogenesis of anaphylactic shock 
[5, 6]. Chemical mediators released not only locally 
from immunologically activated cardiac mast cells 
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but also from tissues other than the heart would 
cause a marked constriction of coronary vessels, 
cardiac arrhythmias, and negative inotropism 
[7, 8]. In anaphylactic shock, therefore, myocardial 
dysfunction due to vasospasm-induced coronary 
flow reduction manifesting as ’Kounis syndrome’ 
should always be considered.
We believe that both vascular dysfunction to 
decrease circulating blood volume and coronary 
spasm-induced myocardial dysfunction underlie the 
development of anaphylactic shock. As Dr Kounis 
and Dr Soufras suggested, further experimental 
and clinical studies are necessary to determine 
the importance of myocardial ischemia via coro-
nary spasm and effects of chemical mediators for 
development of anaphylactic shock, as well as to 
propose new therapeutic approach including the 
protection of cardiac tissue.
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